Enanta Pharmaceuticals Reports Q3 2026 Revenue Decline to $14.4 Million

Enanta Pharmaceuticals, Inc. reported its financial results for the third quarter of fiscal 2026, revealing a total revenue of $14.4 million for the three months ended June 30, 2026, a decrease from $18.3 million in the same period last year. The decline in revenue was primarily attributed to lower reported sales of AbbVie’s MAVYRET/MAVIRET, which is the source of the company's royalty revenue. For the nine months ended June 30, 2026, total revenue remained relatively stable at $50.1 million compared to $50.2 million for the same period in 2025. The company reported a net loss of $19.5 million for the quarter, slightly higher than the $18.3 million loss reported in the prior year, while the nine-month net loss decreased to $44.5 million from $63.2 million.

Operating expenses for the third quarter were $31.6 million, down from $37.2 million in the same quarter of 2025. This reduction was driven by a significant decrease in research and development expenses, which fell to $22.1 million from $27.2 million, reflecting the timing of clinical trials in the company's respiratory syncytial virus (RSV) programs. General and administrative expenses also decreased to $9.5 million from $10.0 million, primarily due to lower stock-based compensation costs. The company’s interest expense increased to $4.1 million, up from $1.6 million, largely due to higher forecasted royalties related to the royalty sale agreement with OMERS.

Enanta's balance sheet as of June 30, 2026, showed total assets of $296.9 million, an increase from $280.7 million at the end of the previous fiscal year. The company had cash, cash equivalents, and marketable securities totaling $211.5 million, which it believes will be sufficient to fund its operating expenses and capital requirements into fiscal 2029. The company’s stockholders' equity rose to $101.1 million, up from $64.7 million, reflecting the issuance of common stock in a public offering completed in October 2025.

Strategically, Enanta continues to advance its clinical programs, particularly in RSV and immunology. The company is preparing to initiate a registrational Phase 2b/3 clinical trial for its RSV candidate, zelicapavir, in high-risk adult populations, with topline data expected in 2027. Additionally, the company is conducting a Phase 1 clinical trial for its immunology candidate, EDP-978, which targets chronic spontaneous urticaria. Enanta's ongoing collaboration with AbbVie remains a critical component of its revenue generation, with the company retaining 45.5% of future royalty payments from MAVYRET/MAVIRET sales through a royalty sale agreement.

Looking ahead, Enanta anticipates continued operating losses as it invests in its research and development programs. The company may seek additional funding through equity offerings or collaborations to support its ongoing initiatives. The management remains optimistic about the potential of its product candidates and the overall market opportunities in virology and immunology, particularly as it navigates the complexities of clinical development and regulatory approvals.